المؤلفون: Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE

المصدر: Patient Preference and Adherence, Vol Volume 13, Pp 561-576 (2019)

مصطلحات موضوعية: T2D mellitus, discrete choice experiment, GLP-1 RA, insulin, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: https://www.dovepress.com/patient-preferences-for-glucagon-like-peptide-1-receptor-agonist-treat-peer-reviewed-article-PPA; https://doaj.org/toc/1177-889X

URL الوصول: https://doaj.org/article/3df7d3ed54f642ebbeef6dacb9645075

المؤلفون: Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE

المصدر: Patient Preference and Adherence, Vol Volume 10, Pp 1573-1581 (2016)

مصطلحات موضوعية: Adherence, Complications, Costs, Resource Utilization, Retrospective Study, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: https://www.dovepress.com/associations-between-adherence-and-outcomes-among-older-type-2-diabete-peer-reviewed-article-PPA; https://doaj.org/toc/1177-889X

URL الوصول: https://doaj.org/article/37c2b1e50c9b48d9b7c3cf385c71b926

المؤلفون: Cukierman-Yaffe, T, Gerstein, HC, Colhoun, HM, Diaz, R, Garcia-Perez, LE, Lakshmanan, M, Bethel, A, Xavier, D, Probstfield, J, Riddle, MC, Ryden, L, Atisso, CM, Hall, S, Rao-Melacini, P, Basile, J, Cushman, WC, Franek, E, Keltai, M, Lanas, F, Leiter, LA, Lopez-Jaramillo, P, Pirags, V, Pogosova, N, Raubenheimer, PJ, Shaw, JE, Sheu, WHH, Temelkova-Kurktschiev, T

المصدر: The Lancet. Neurology. 19(7):582-590

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:144083948

المؤلفون: Boye, K, Lebrec, J, Sapin, H, Guerci, B, Giorgino, F, Füchtenbusch, M, Heitmann, E, Orsini Federici, M, Dib, A, García-Pérez, LE

المصدر: In Value in Health January 2022 25(1) Supplement:S242-S242

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: le Roux CW; Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland., Hankosky ER; Eli Lilly and Company, Indianapolis, Indiana, USA., Wang D; Eli Lilly and Company, Indianapolis, Indiana, USA., Malik R; Eli Lilly and Company, Indianapolis, Indiana, USA., Yu M; Eli Lilly and Company, Indianapolis, Indiana, USA., Hickey A; Eli Lilly and Company, Indianapolis, Indiana, USA., Kan H; Eli Lilly and Company, Indianapolis, Indiana, USA., Bunck MC; Eli Lilly and Company, Indianapolis, Indiana, USA., Stefanski A; Eli Lilly and Company, Indianapolis, Indiana, USA., Garcia-Perez LE; Eli Lilly and Company, Indianapolis, Indiana, USA., Wharton S; McMaster University, York University and Wharton Weight Management Clinic, Toronto, Ontario, Canada.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Sep; Vol. 25 (9), pp. 2626-2633. Date of Electronic Publication: 2023 Jun 21.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Hypoglycemic Agents* , Diabetes Mellitus, Type 2*, Humans ; Glucagon-Like Peptides/adverse effects ; Obesity/drug therapy ; Body Weight ; Weight Loss

المؤلفون: Boye KS; Eli Lilly and Company, Indianapolis, Indiana., Riddle MC; Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, Oregon., Gerstein HC; McMaster University and Hamilton Health Sciences Center, Population Health Research Institute, Hamilton, Ontario, Canada., Mody R; Eli Lilly and Company, Indianapolis, Indiana., Garcia-Perez LE; Lilly S.A., Alcobendas, Spain., Karanikas CA; Eli Lilly and Company, Indianapolis, Indiana., Lage MJ; HealthMetrics Outcomes Research, Bonita Springs, Florida., Riesmeyer JS; Eli Lilly and Company, Indianapolis, Indiana., Lakshmanan MC; Eli Lilly and Company, Indianapolis, Indiana.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2019 Jun; Vol. 21 (6), pp. 1299-1304. Date of Electronic Publication: 2019 Mar 12.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Cardiovascular Diseases*/complications , Cardiovascular Diseases*/epidemiology , Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/epidemiology , Hypoglycemic Agents*/adverse effects , Hypoglycemic Agents*/therapeutic use, Glucagon-Like Peptide-1 Receptor/*agonists, Aged ; Female ; Glucagon-Like Peptides/adverse effects ; Glucagon-Like Peptides/analogs & derivatives ; Glucagon-Like Peptides/therapeutic use ; Humans ; Immunoglobulin Fc Fragments/adverse effects ; Immunoglobulin Fc Fragments/therapeutic use ; Male ; Middle Aged ; Randomized Controlled Trials as Topic ; Recombinant Fusion Proteins/adverse effects ; Recombinant Fusion Proteins/therapeutic use ; Retrospective Studies ; United States

المؤلفون: Gallwitz B; University of Tübingen, Tübingen, Germany., Dagogo-Jack S; University of Tennessee Health Science Center, Memphis, Tennessee., Thieu V; Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana., Garcia-Perez LE; Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana., Pavo I; Eli Lilly Regional Operations, Vienna, Austria., Yu M; Eli Lilly Canada, Toronto, Canada., Robertson KE; Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana., Zhang N; Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana., Giorgino F; University of Bari Aldo Moro, Bari, Italy.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Feb; Vol. 20 (2), pp. 409-418. Date of Electronic Publication: 2017 Oct 05.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2/*drug therapy , Glucagon-Like Peptide-1 Receptor/*agonists , Glucagon-Like Peptides/*analogs & derivatives , Hyperglycemia/*prevention & control , Hypoglycemia/*prevention & control , Hypoglycemic Agents/*administration & dosage , Immunoglobulin Fc Fragments/*administration & dosage , Recombinant Fusion Proteins/*administration & dosage, Aged ; Blood Glucose/analysis ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/metabolism ; Diarrhea/chemically induced ; Drug Administration Schedule ; Drug Therapy, Combination/adverse effects ; Female ; Glucagon-Like Peptide-1 Receptor/metabolism ; Glucagon-Like Peptides/administration & dosage ; Glucagon-Like Peptides/adverse effects ; Glucagon-Like Peptides/therapeutic use ; Glycated Hemoglobin/analysis ; Humans ; Hypoglycemia/chemically induced ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Immunoglobulin Fc Fragments/adverse effects ; Immunoglobulin Fc Fragments/therapeutic use ; Insulin/administration & dosage ; Insulin/adverse effects ; Insulin/therapeutic use ; Male ; Middle Aged ; Nausea/chemically induced ; Recombinant Fusion Proteins/adverse effects ; Recombinant Fusion Proteins/therapeutic use ; Sex Characteristics ; Vomiting/chemically induced ; Weight Gain/drug effects ; Weight Loss/drug effects

المؤلفون: Curtis SE, Boye KS, Lage MJ; HealthMetrics Outcomes Research, 27576 River Reach Dr, Bonita Springs, FL 34134. E-mail: lagemj@hlthmetrics.com., Garcia-Perez LE

المصدر: The American journal of managed care [Am J Manag Care] 2017 Jul 01; Vol. 23 (7), pp. e208-e214. Date of Electronic Publication: 2017 Jul 01.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Clinical Care Targeted Communications Group, LLC Country of Publication: United States NLM ID: 9613960 Publication Model: Electronic Cited Medium: Internet ISSN: 1936-2692 (Electronic) Linking ISSN: 10880224 NLM ISO Abbreviation: Am J Manag Care

مواضيع طبية MeSH: Diabetes Mellitus, Type 2/*drug therapy , Health Expenditures/*statistics & numerical data , Hypoglycemic Agents/*therapeutic use , Medication Adherence/*statistics & numerical data, Adolescent ; Adult ; Emergency Service, Hospital/statistics & numerical data ; Female ; Hospitalization/statistics & numerical data ; Humans ; Hypoglycemic Agents/administration & dosage ; Insurance Claim Review ; Male ; Middle Aged ; Retrospective Studies ; Young Adult

المؤلفون: Anderson JE; a The Frist Clinic , Nashville , TN , USA., Thieu VT; b Global Medical Affairs , Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA., Boye KS; c Global Patient Outcomes , Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA., Hietpas RT; d Global Scientific Communications , Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA., Garcia-Perez LE; b Global Medical Affairs , Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA.

المصدر: Postgraduate medicine [Postgrad Med] 2016 Nov; Vol. 128 (8), pp. 810-821. Date of Electronic Publication: 2016 Aug 12.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 0401147 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-9260 (Electronic) Linking ISSN: 00325481 NLM ISO Abbreviation: Postgrad Med Subsets: MEDLINE

مواضيع طبية MeSH: Primary Health Care*, Diabetes Mellitus, Type 2/*drug therapy , Glucagon-Like Peptides/*analogs & derivatives , Hypoglycemic Agents/*therapeutic use , Immunoglobulin Fc Fragments/*therapeutic use , Recombinant Fusion Proteins/*therapeutic use, Blood Glucose ; Body Weight/drug effects ; Clinical Trials, Phase III as Topic ; Drug Therapy, Combination ; Glucagon-Like Peptides/administration & dosage ; Glucagon-Like Peptides/adverse effects ; Glucagon-Like Peptides/therapeutic use ; Glycated Hemoglobin ; Humans ; Hypoglycemia/chemically induced ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Immunoglobulin Fc Fragments/administration & dosage ; Immunoglobulin Fc Fragments/adverse effects ; Injections, Subcutaneous/instrumentation ; Patient Reported Outcome Measures ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects